Real-Life Effectiveness of Tildrakizumab in Chronic Palmo Plantar Psoriasis: A Case Series of 7 Patients with 28 weeks of Follow Up

Abstract

Palmo-plantar psoriasis (PPP) is highly debilitating and difficult to treat impairing quality of life of patients. Tildrakizumab is an anti-IL23p19 subunit monoclonal antibody approved for the treatment of moderate-severe chronic plaque psoriasis in adult candidates for systemic therapy. Objective of this study is to investigate the safety and efficacy of tildrakizumab in the management of palmo-plantar psoriasis. A total of 7 adults patients with moderate to severe PPP were retrospective analysed. Tildrakizumab 100 mg was administered at weeks 0, 4 and then every 12 weeks, by subcutaneous injection. Patients were visited at baseline, at week 16 and at week 28. Safety and efficacy were assessed at weeks 0, 16 and 28. Physician's Global Assessment (PGA) and Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) clinical score were used to measure the efficacy. The mean PGA score was reduced from 3.6 at baseline to 1.7 after 16 weeks and 1.3 after 28 weeks. The mean PPPASI score was reduced from 19.2 at baseline to 9.2 after 16 weeks and 5.2 after 28 weeks. In conclusion tildrakizumab represents a safe and effective treatment for psoriasis even in difficult areas such as the palms and soles.